Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2025 | Story André Damons | Photo Supplied
Prof Wynand Goosen
Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards.

Being nominated for a ‘Science Oscar’ is exciting and validates nominees’ efforts, particularly in a field as challenging and essential as infectious diseases, for which they are recognised at the highest level. 

This is according to Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State (UFS). He was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards for his landmark discovery of Mycobacterium bovis infection in humans in South Africa – the first confirmed cases in the country. 

Prof Goosen, who previously won the NSTF-South32 Emerging Researcher Award, says the nomination is a powerful affirmation of the impact that focused, interdisciplinary research can have. It reflects not only his personal commitment but also the dedication of a talented and hard-working team. “I am honoured and humbled to be nominated. It is also a testament to the support and vision of UFS, particularly as we position ourselves as leaders in One Health research in South Africa,” he says. 

 

Focus of research 

He was nominated by Prof Vasu Reddy, UFS Deputy Vice-Chancellor: Research and Internationalisation, and Prof Paul Oberholster, Dean for the Faculty of Natural and Agricultural Sciences (NAS) at the UFS, and Prof Nico Gey van Pittius and Prof Elmi Muller from Stellenbosch University (US). The NSTF Awards, known as the ‘Science Oscars’of SA, honour, reward, celebrate, profile and promote outstanding contributions to science, engineering and technology (SET) and innovation in South Africa.

“The nomination,” Prof Goosen continues, “recognises our work in the field of zoonotic tuberculosis (TB) and other emerging infectious diseases at the human-animal-environment interface. Our research focuses on the molecular detection and characterisation of pathogenic mycobacteria in wildlife, livestock, and human populations, with the aim of informing better surveillance, diagnostics, and control strategies — particularly in high-risk ecosystems. This includes novel applications in wildlife TB surveillance and understanding the transmission dynamics between animals and people.”

 

Establishing a Kovsie One Health Research Unit

This research is critically important as South Africa continues to face a high burden of tuberculosis, including zoonotic TB, which often goes under-detected in rural and wildlife-rich areas. Understanding how these pathogens circulate between humans, animals, and the environment, explains Prof Goosen, is essential for effective disease control and to mitigate future pandemics. This work directly supports national health priorities, informs policy, and contributes to global strategies for One Health.

Prof Goosen and the team are in the process of laying the groundwork for the establishment of a Kovsie One Health Research Unit, which will serve as a collaborative platform for research spanning human, animal, and environmental health. One of their key projects involves expanding TB and AMR surveillance in wildlife-livestock-human interfaces, using cutting-edge diagnostics and genomic tools. They are also initiating partnerships with industry and international institutions to address emerging zoonoses and environmental pathogens in a transdisciplinary manner.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept